Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | PPARD | Q03181 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421346 | 0.89 | MRGPRX4 (0.56) | MAOBMRGPRX4MAOAPPARAPPARD | |
| SCHEMBL4422282 | 0.85 | MAOB (0.78) | MAOBMAOAPPARANR4A2 | |
| SCHEMBL2997270 | 0.84 | MAOB (0.62) | MAOBMRGPRX4MAOANR4A2 | |
| Hydrochloric Acid SCHEMBL9015457 | 0.82 | MAOB (0.61) | MAOBMRGPRX4MAOANR4A2 | |
| SCHEMBL15350813 | 0.81 | KDM4E (0.51) | MAOBMAOA | |
| SCHEMBL6470900 | 0.80 | MAOB (0.51) | MAOBMAOA | |
| SCHEMBL6525591 | 0.80 | MAOB (0.76) | MAOBMRGPRX4PPARANR4A2 | |
| SCHEMBL19951231 | 0.80 | MAOB (0.76) | MAOBMRGPRX4PPARANR4A2 | |
| SCHEMBL6439462 | 0.80 | MAOB (0.56) | MAOBMRGPRX4MAOAPPARAPPARD | |
| SCHEMBL3504962 | 0.79 | MAOB (0.50) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515926-B1 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| CN-1274669-C | Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia | HOFFMANN LA ROCHE (CH) | 2006-09-13 | — | — | CN | disclosed |
| US-6951884-B2 | Fluorobenzamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| CN-1659135-A | Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia | HOFFMANN LA ROCHE (CH) | 2005-08-24 | — | — | CN | disclosed |
| EP-1515926-A2 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | F.HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20030236304-A1 | Fluorobenzamides and uses thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-25 | — | — | US | disclosed |
| WO-2003106380-A2 | FLUOROBENZAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236304-A1 | Fluorobenzamides and uses thereof | MAOB, MAOA, BCHE | MAOB 1/4885MRGPRX4 1009/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.